Search by Drug Name or NDC
NDC 00469-2460-28 VEOZAH 45 mg/1 Details
VEOZAH 45 mg/1
VEOZAH is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Astellas Pharma US, Inc.. The primary component is FEZOLINETANT.
MedlinePlus Drug Summary
Fezolinetant is used to treat moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause. Fezolinetant is in a class of medications called neurokinin 3 (NK3) receptor antagonist. It works by altering the nerve response that triggers the thermoregulatory center causing vasomotor symptoms.
Related Packages: 00469-2460-28Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Fezolinetant
Product Information
| NDC | 00469-2460 |
|---|---|
| Product ID | 0469-2460_dd7b6095-12cc-43e0-be7f-b53a0a0794f3 |
| Associated GPIs | |
| GCN Sequence Number | 084780 |
| GCN Sequence Number Description | fezolinetant TABLET 45 MG ORAL |
| HIC3 | G6B |
| HIC3 Description | MENOPAUSAL SYMPTOMS SUPPRESSANT-NK3 RECEPTOR ANTAG |
| GCN | 54158 |
| HICL Sequence Number | 048921 |
| HICL Sequence Number Description | FEZOLINETANT |
| Brand/Generic | Brand |
| Proprietary Name | VEOZAH |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | fezolinetant |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 45 |
| Active Ingredient Units | mg/1 |
| Substance Name | FEZOLINETANT |
| Labeler Name | Astellas Pharma US, Inc. |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA216578 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00469-2460-28 (00469246028)
| NDC Package Code | 0469-2460-28 |
|---|---|
| Billing NDC | 00469246028 |
| Package | 4 CARTON in 1 TRAY (0469-2460-28) / 1 BOTTLE in 1 CARTON (0469-2460-07) / 7 TABLET, FILM COATED in 1 BOTTLE |
| Marketing Start Date | 2023-05-16 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |